2022
Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer
Saeed N, Jin L, Amini A, Verma V, Lester-Coll N, Chen P, Decker R, Park H. Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer. American Journal Of Clinical Oncology 2022, 46: 66-72. PMID: 36662872, DOI: 10.1097/coc.0000000000000974.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage I non-small cell lung cancerOverall survivalCell lung cancerLung cancerStereotactic body radiation therapyNational Cancer DatabaseLog-rank testBody radiation therapyOptimal fractionation scheduleMultivariable modeling techniquesOS benefitHypofractionated radiotherapySurvival impactMultivariable analysisCox regressionCancer DatabaseRetrospective analysisFractionation schedulesRadiation therapyHFRTPatientsCFRTRadiotherapyKaplan-Meier estimatorImmunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Park HS, Goldberg SB, Boffa DJ. Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer. JAMA Network Open 2022, 5: e2224478. PMID: 35925606, PMCID: PMC9353596, DOI: 10.1001/jamanetworkopen.2022.24478.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Non-Small-Cell LungCohort StudiesFemaleHumansImmunotherapyLung NeoplasmsMaleNeoplasm StagingConceptsStage III non-small cell lung cancerNon-small cell lung cancerClinical stage III non-small cell lung cancerUnresectable stage III non-small cell lung cancerPropensity-matched sampleGeneral US populationSurvival advantageCohort studyLung cancerMultivariable Cox proportional hazards modelsUS populationStage III lung cancerMedian age 66 yearsCox proportional hazards modelNational Cancer DatabaseEfficacy of immunotherapyAge 66 yearsProtocol rangesCell lung cancerClinical trial populationsProportional hazards modelTerms of ageImmunotherapy initiationImmunotherapy recipientsImmunotherapy use
2021
A reply to “Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC”
Jairam V, Soulos PR, Gross CP, Yu JB, Park HS, Decker RH. A reply to “Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC”. Lung Cancer 2021, 168: 84-85. PMID: 34933760, DOI: 10.1016/j.lungcan.2021.12.003.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsRadiotherapy, ConformalRadiotherapy, Intensity-ModulatedClinical Outcomes and Safety Profile in the Treatment of Synchronous Nonmetastatic Lung Tumors With Stereotactic Body Radiation Therapy
Raju SC, Peters GW, Decker RH, Park HS. Clinical Outcomes and Safety Profile in the Treatment of Synchronous Nonmetastatic Lung Tumors With Stereotactic Body Radiation Therapy. Practical Radiation Oncology 2021, 12: e110-e116. PMID: 34861443, DOI: 10.1016/j.prro.2021.11.006.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyPrimary lung tumorsSynchronous primary lung tumorsAdverse events gradeCommon Terminology CriteriaBody radiation therapyLung tumorsNew primaryTerminology CriteriaOverall survivalClinical outcomesLung cancerRadiation therapyEvents gradeEarly-stage primary lung cancerMedian progression-free survivalEffective doseDistant failure ratesLocal failure rateMedian overall survivalMedian total dosePrimary lung cancerProgression-free survivalPatterns of recurrenceNonmetastatic lung cancerPost-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques
Jairam V, Pasha S, Soulos PR, Gross CP, Yu JB, Park HS, Decker RH. Post-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques. Lung Cancer 2021, 161: 171-179. PMID: 34607209, DOI: 10.1016/j.lungcan.2021.09.010.Peer-Reviewed Original ResearchConceptsPost-operative radiation therapyNon-small cell lung cancerCell lung cancerRadiation therapyPropensity-score matchingLA-NSCLCCardiac toxicityLung cancerAdvanced non-small cell lung cancerClinical risk factorsProportion of patientsMultivariable logistic regressionPrior treatment historyPredictors of receiptUse of IMRTConformal radiation therapyLong-term toxicityChi-squared testRadiation therapy techniquesRadiotherapy treatment techniquesUpfront surgeryElderly patientsTreatment toxicityMean ageMedicare databaseRates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ
Talcott WJ, Miccio JA, Park HS, White AA, Kozono DE, Singer L, Sands JM, Sholl LM, Detterbeck FC, Mak RH, Decker RH, Kann BH. Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ. Lung Cancer 2021, 157: 17-20. PMID: 34052704, DOI: 10.1016/j.lungcan.2021.05.028.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerBiopsy suggestiveInvasive diseaseSitu diseaseSquamous histologySurvival outcomesTumor sizeObserved cohortNational Cancer DatabaseExcellent survival outcomesHalf of patientsCell lung cancerMultivariable logistic regressionResection of lesionsAdenocarcinoma histologyDefinitive therapyNSCLC patientsOverall survivalLocal therapyRisk stratificationLung cancerCancer DatabaseResectionSurgical pathologyLesion size
2020
Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials
Pathak R, De Lima Lopes G, Yu H, Aryal MR, Ji W, Frumento KS, Wallis CJD, Klaassen Z, Park HS, Goldberg SB. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non–small cell lung cancer: A network meta‐analysis of randomized trials. Cancer 2020, 127: 709-719. PMID: 33119177, DOI: 10.1002/cncr.33269.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerSingle-agent ICICell lung cancerPD-L1Lung cancerAdditional overall survival benefitsEfficacy of chemoimmunotherapyFirst-line ICIHigh PD-L1Overall survival benefitCochrane Central RegisterFirst-line treatmentPD-L1 statusPhase 3 trialLow PD-L1Absence of headSignificant differencesRandom-effects modelBayesian random-effects modelImproved PFSOS benefitEfficacy outcomesEligible trialsCentral RegisterLocal Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
Jairam V, Park HS, Decker RH. Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer. The Cancer Journal 2020, 26: 129-136. PMID: 32205537, DOI: 10.1097/ppo.0000000000000433.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerLocal ablative therapyOligoprogressive non-small cell lung cancerCell lung cancerAblative therapyMetastatic diseaseLung cancerMetastatic non-small cell lung cancerTime of diagnosisLong-term survivalLimited metastasesOligometastatic diseaseMetastatic patientsSystemic therapyRadiofrequency ablationDisease progressionPatient outcomesStereotactic radiotherapyTherapyPatientsDiseaseAccumulation of evidenceCancerProgressionComplex diseases
2019
Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma
Kann BH, Verma V, Stahl JM, Ross R, Dosoretz AP, Shafman TD, Gross CP, Park HS, Yu JB, Decker RH. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma. Radiotherapy And Oncology 2019, 134: 44-49. PMID: 31005223, DOI: 10.1016/j.radonc.2019.01.027.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaStereotactic body radiation therapyProgression-free survivalEarly-stage non-small cell lung carcinomaOperable patientsBody radiation therapyCell lung carcinomaOverall survivalLocal failureLung carcinomaRadiation therapyInoperable early stage non-small cell lung carcinomaDefinitive stereotactic body radiation therapyLack of resectionPoor surgical candidacyRetrospective cohort studyKaplan-Meier methodologyHigher overall survivalDisease-related outcomesMulti-institutional analysisDocumentation of patientsStandard of careMulti-institutional studyCohort studyInoperable patients
2018
Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis
Kann BH, Miccio JA, Stahl JM, Ross R, Verma V, Dosoretz AP, Park HS, Shafman TD, Gross CP, Yu JB, Decker RH. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis. Radiotherapy And Oncology 2018, 132: 188-196. PMID: 30391106, DOI: 10.1016/j.radonc.2018.10.017.Peer-Reviewed Original ResearchConceptsNon-small cell lung carcinomaStereotactic body radiotherapyAdjuvant systemic therapyEarly-stage non-small cell lung carcinomaSystemic therapyMulti-institutional analysisCell lung carcinomaOverall survivalST patientsBody radiotherapyLung carcinomaDefinitive stereotactic body radiotherapyEarly-stage NSCLC patientsClinical risk factorsRetrospective cohort studyKaplan-Meier methodHigher T stageTreatment of patientsMulti-institutional databasePropensity-score matchingPlatinum doubletsST cohortST regimenCohort studyNSCLC patientsAssociation Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non–Small Cell Lung Cancer
Wang EH, Corso CD, Park HS, Chen AB, Wilson LD, Kim AW, Decker RH, Yu JB. Association Between Radiation Dose and Outcomes With Postoperative Radiotherapy for N0-N1 Non–Small Cell Lung Cancer. American Journal Of Clinical Oncology 2018, 41: 152-158. PMID: 26523443, DOI: 10.1097/coc.0000000000000245.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAgedCarcinoma, Non-Small-Cell LungCohort StudiesDatabases, FactualDisease-Free SurvivalDose-Response Relationship, RadiationFemaleHumansLung NeoplasmsMaleMargins of ExcisionMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingPneumonectomyPrognosisProportional Hazards ModelsRadiotherapy DosageRadiotherapy, AdjuvantRadiotherapy, Intensity-ModulatedRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsNon-small cell lung cancerPostoperative radiotherapyCell lung cancerIntensity-modulated radiation therapyPORT doseOverall survivalLung cancerRadiation therapyUse of PORTNational Cancer Data BaseStage IIProportion of patientsGroup of patientsProportional hazards regressionEvidence of benefitSurgical resectionWorse survivalMultivariable analysisHazards regressionRetrospective studyConformal radiationPatientsRadiotherapy techniquesRadiation modalitiesModern treatment
2017
Dose-Volume Predictors of Esophagitis After Thoracic Stereotactic Body Radiation Therapy
Harder EM, Chen Z, Park HS, Mancini BR, Decker RH. Dose-Volume Predictors of Esophagitis After Thoracic Stereotactic Body Radiation Therapy. American Journal Of Clinical Oncology 2017, 40: 477-482. PMID: 26017483, DOI: 10.1097/coc.0000000000000195.Peer-Reviewed Original ResearchConceptsStepwise selection techniqueRadiation therapyThoracic stereotactic body radiation therapyStereotactic hypofractionated radiation therapyStereotactic body radiation therapyDose-volume predictorsNormal tissue complication probabilityHypofractionated radiation therapyMultivariate logistic regressionProbability estimatesBody radiation therapyPlanning target volumeEsophageal toxicityEsophagitis ratesCTCAE v4.0Dosimetric predictorsPulmonary tumorsInstitutional databaseRadiotherapy parametersUse of Alternative Medicine for Cancer and Its Impact on Survival
Johnson SB, Park HS, Gross CP, Yu JB. Use of Alternative Medicine for Cancer and Its Impact on Survival. Journal Of The National Cancer Institute 2017, 110: djx145. PMID: 28922780, DOI: 10.1093/jnci/djx145.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsBreast NeoplasmsChoice BehaviorColorectal NeoplasmsComorbidityComplementary TherapiesEducational StatusFemaleHumansIncomeLung NeoplasmsMaleNeoplasm StagingNorthwestern United StatesPacific StatesPatient PreferenceProstatic NeoplasmsResidence CharacteristicsSex FactorsSurvival RateConceptsConventional cancer treatmentsAlternative medicineColorectal cancerCox proportional hazards regressionGreater riskLower comorbidity scoreMultivariable logistic regressionProportional hazards regressionPatterns of utilizationHigher socioeconomic statusNonmetastatic breastComorbidity scoreHormone therapyCurable cancerHazards regressionLung cancerAM useAnticancer treatmentStage IICancerIndependent covariatesLogistic regressionPatientsCancer treatmentSocioeconomic statusStage I Lung SBRT Clinical Practice Patterns
Corso CD, Park HS, Moreno AC, Kim AW, Yu JB, Husain ZA, Decker RH. Stage I Lung SBRT Clinical Practice Patterns. American Journal Of Clinical Oncology 2017, 40: 358-361. PMID: 25503436, DOI: 10.1097/coc.0000000000000162.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyNational Cancer DatabaseStage I non-small cell lung cancer patientsUse of SBRTNon-small cell lung cancer patientsCell lung cancer patientsStage I NSCLCMajority of patientsClinical practice patternsLung cancer patientsBody radiation therapyMedian BED10SBRT useDosing guidelinesRetrospective studyCancer patientsPrescription trendsCancer DatabasePractice patternsRadiation therapyPatientsDose prescriptionGyRegimensCommon prescription
2016
Trends in stereotactic body radiation therapy for stage I small cell lung cancer
Stahl JM, Corso CD, Verma V, Park HS, Nath SK, Husain ZA, Simone CB, Kim AW, Decker RH. Trends in stereotactic body radiation therapy for stage I small cell lung cancer. Lung Cancer 2016, 103: 11-16. PMID: 28024690, DOI: 10.1016/j.lungcan.2016.11.009.Peer-Reviewed Original ResearchConceptsStage I small cell lung cancerNational Cancer Data BaseSmall cell lung cancerCell lung cancerMultivariable logistic regressionSBRT utilizationLung cancerDose prescriptionLogistic regressionStereotactic body radiation therapyInitial treatment allocationClinical stage IDefinitive surgical managementAdministration of chemotherapyKaplan-Meier methodBody radiation therapyRadiation therapy utilizationSBRT useChemotherapy useInoperable patientsMedian survivalChemotherapy administrationOverall survivalSurgical managementTherapy utilizationHospital Volume and Outcomes of Robot-Assisted Lobectomies
Tchouta LN, Park HS, Boffa DJ, Blasberg JD, Detterbeck FC, Kim AW. Hospital Volume and Outcomes of Robot-Assisted Lobectomies. CHEST Journal 2016, 151: 329-339. PMID: 27687847, DOI: 10.1016/j.chest.2016.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCase-Control StudiesCohort StudiesDatabases, FactualFemaleHospital MortalityHospitals, High-VolumeHospitals, Low-VolumeHumansLength of StayLinear ModelsLogistic ModelsLungLung NeoplasmsMaleMiddle AgedMultivariate AnalysisPneumonectomyPostoperative ComplicationsRetrospective StudiesRobotic Surgical ProceduresThoracic Surgery, Video-AssistedTreatment OutcomeConceptsLength of stayLow-volume centersHospital volumeClinical impactHealth care system-related factorsShorter mean LOSUtilization Project National Inpatient Sample databaseVolume/outcome relationshipLong-term clinical impactMean LOSNational Inpatient Sample databaseShorter LOSVideo-assisted thoracoscopic surgeryHospital operative volumeHigh-volume hospitalsIncidence of complicationsHigher hospital volumeThoracoscopic surgery lobectomyAnnual case volumeSystem-related factorsOutcomes of interestLOS outcomesInfectious complicationsInpatient mortalityIndependent predictorsElderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients
Mancini BR, Park HS, Harder EM, Rutter CE, Corso CD, Decker RH, Husain ZA. Elderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients. Lung Cancer 2016, 97: 22-27. PMID: 27237023, DOI: 10.1016/j.lungcan.2016.04.011.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerEarly-stage non-small cell lung cancerStereotactic body radiation therapyNon-elderly patientsElderly patientsDistant controlOverall survivalYounger patientsInoperable early-stage non-small cell lung cancerUse of SBRTStage non-small cell lung cancerLocal controlMultivariable Cox proportional hazards analysisCox proportional hazards analysisGrade 5 toxicityNon-elderly cohortProportional hazards analysisCell lung cancerRisk of complicationsRate of efficacyBody radiation therapyLogistic regression analysisLate gradeAcute gradeSurgical resectionPulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy
Harder EM, Park HS, Chen Z, Decker RH. Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy. Practical Radiation Oncology 2016, 6: e353-e359. PMID: 27156424, DOI: 10.1016/j.prro.2016.01.015.Peer-Reviewed Original ResearchConceptsMean lung doseStereotactic body radiation therapyRisk of gradeRadiation pneumonitisMultivariable logistic regressionBody radiation therapyDosimetric predictorsRadiation therapyMaximum doseLogistic regressionRP rateBest dosimetric predictorCardiac dosimetric parametersDose-volume predictorsPercent of lungVolume of lungGross tumor volumeBackward stepwise eliminationLung V10Lung doseMean doseTotal lungUnivariate analysisPulmonary volumesTumor volume
2015
Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer
Corso CD, Rutter CE, Park HS, Lester-Coll NH, Kim AW, Wilson LD, Husain ZA, Lilenbaum RC, Yu JB, Decker RH. Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer. Journal Of Clinical Oncology 2015, 33: 4240-4246. PMID: 26481366, PMCID: PMC4678178, DOI: 10.1200/jco.2015.62.4270.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyComorbidityDatabases, FactualFemaleHumansKaplan-Meier EstimateLung NeoplasmsMaleNeoplasm StagingOdds RatioPropensity ScoreRetrospective StudiesSex FactorsSmall Cell Lung CarcinomaTime FactorsTreatment OutcomeUnited StatesConceptsElderly patientsOverall survivalSurvival benefitLung cancerLimited-stage small cell lung cancerCancer clinical stage IClinical stage III diseaseNational Cancer Data BaseCox proportional hazards regressionPropensity scoreSmall cell lung cancerLarge population-based cohortLimited-Stage SmallRole of chemoradiotherapyClinical stage IStage III diseaseUse of chemoradiotherapyCell lung cancerPopulation-based cohortProportional hazards regressionLog-rank testMixed-effects logistic regressionLarge national databaseOS advantageSequential chemoradiotherapyComparison of survival outcomes among standard radiotherapy regimens in limited-stage small cell lung cancer patients receiving concurrent chemoradiation
Rutter CE, Park HS, Corso CD, Yeboa DN, Mancini BR, Lester-Coll NH, Kim AW, Decker RH. Comparison of survival outcomes among standard radiotherapy regimens in limited-stage small cell lung cancer patients receiving concurrent chemoradiation. Lung Cancer 2015, 90: 243-248. PMID: 26277031, DOI: 10.1016/j.lungcan.2015.08.002.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerDose-fractionation regimensLimited-stage small cell lung cancerConcurrent CRTConcurrent chemoradiationOverall survivalLimited-stage small-cell lung cancer patientsProportional hazardsSmall cell lung cancer patientsMultivariable Cox proportional hazardsCell lung cancer patientsOptimal radiotherapy doseOngoing randomized trialsInferior overall survivalKaplan-Meier analysisCell lung cancerLarger tumor sizeMedian survival timeLung cancer patientsCox proportional hazardsStandard radiotherapy regimensLarge national datasetChemoradiation regimensSimilar OSEquivalent OS